The ID Now COVID-19 test is the second assay from the company to receive EUA from the FDA, following the same designation issued to the Abbott RealTime SARS CoV-2.
The NxTag CoV Extended Panel is a multiplex PCR test that uses the company's bead-based NxTag technology to detect coronavirus in nasopharyngeal swab specimens.
The BGI Real-Time Fluorescent RT-PCR Kit for detecting SARS-2019-nCoV runs in approximately three hours and can be manufactured in large volumes, the firm has said.
The AvellinoCoV2 real-time PCR test is designed for the detection of nucleic acid from SARS-CoV-2 from nasopharyngeal and oropharyngeal swab specimens.
University of Oxford researchers said they are weeks away from completing clinical validation of a coronavirus molecular test based on RT-LAMP technology.
The anti-SARS-CoV-2 antibodies for classes IgA and IgG are two of the first antibody detection tests to receive CE making and be made available for SARS-CoV-2 testing.
Such tests indicate whether a person had an immune response to the virus, which could aid infection tracking and identifying individuals with immunity.
The point-of-care test is designed for the qualitative presumptive detection of specific IgM and IgG antibodies to SARS-CoV-2 in a fingerstick blood sample.
The test, which uses an Applied Bioystems TaqPath assay and real-time PCR technology, detects nucleic acid from SARS-CoV-2, the virus that causes COVID-19.
Biocartis will lead commercialization in Europe as the exclusive distributor of the SeptiCyte Rapid test, while Immunexpress will lead commercialization of the test in the US.
Now, the assay can also be used with the Applied Biosystems 7500 Standard from Thermo Fisher Scientific, Roche's LightCycler 480, and Qiagen's Rotor-Gene Q.
